Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
NASDAQ:MREO
Price:
3.01 USD
-2.9%
Market Closed
Updated:
May 8, 2024
Balance Sheet
Balance Sheet Decomposition
Mereo Biopharma Group PLC
Mereo Biopharma Group PLC
| Current Assets | 54.2m |
| Cash & Short-Term Investments | 42.1m |
| Receivables | 10.7m |
| Other Current Assets | 1.4m |
| Non-Current Assets | 26.4m |
| PP&E | 1.6m |
| Intangibles | 24.8m |
| Current Liabilities | 17.5m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 4.8m |
| Other Current Liabilities | 10.8m |
| Non-Current Liabilities | 5.4m |
| Long-Term Debt | 4.6m |
| Other Non-Current Liabilities | 797k |
Balance Sheet
Mereo Biopharma Group PLC
Mereo Biopharma Group PLC
Currency: GBP
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
16
|
23
|
94
|
56
|
|
| Cash |
16
|
23
|
94
|
5
|
|
| Cash Equivalents |
1
|
1
|
1
|
51
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
|
| Total Receivables |
12
|
5
|
2
|
3
|
|
| Other Current Assets |
2
|
2
|
3
|
3
|
|
| Total Current Assets |
30
|
30
|
99
|
62
|
|
| PP&E Net |
12
|
2
|
3
|
2
|
|
| PP&E Gross |
12
|
2
|
3
|
2
|
|
| Accumulated Depreciation |
2
|
2
|
2
|
2
|
|
| Intangible Assets |
45
|
32
|
25
|
24
|
|
| Total Assets |
86
N/A
|
63
-27%
|
126
+101%
|
88
-30%
|
|
| Liabilities | |||||
| Accounts Payable |
6
|
3
|
2
|
3
|
|
| Accrued Liabilities |
5
|
4
|
4
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
18
|
1
|
1
|
12
|
|
| Other Current Liabilities |
1
|
0
|
6
|
6
|
|
| Total Current Liabilities |
30
|
9
|
13
|
25
|
|
| Long-Term Debt |
15
|
17
|
16
|
1
|
|
| Other Liabilities |
2
|
52
|
10
|
0
|
|
| Total Liabilities |
46
N/A
|
78
+69%
|
38
-51%
|
26
-32%
|
|
| Equity | |||||
| Common Stock |
0
|
1
|
2
|
2
|
|
| Retained Earnings |
80
|
211
|
160
|
191
|
|
| Additional Paid In Capital |
122
|
162
|
248
|
254
|
|
| Other Equity |
2
|
33
|
1
|
3
|
|
| Total Equity |
40
N/A
|
15
N/A
|
88
N/A
|
62
-30%
|
|
| Total Liabilities & Equity |
86
N/A
|
63
-27%
|
126
+101%
|
88
-30%
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
98
|
339
|
585
|
625
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
